Developer docs
API playgroundTry for free, no card

Search company profiles

Landos Biopharma

Full company profile

uuid0002824

Namestring
Landos Biopharma
Legal namestring
Landos Biopharma, Inc.
Company typeenum
Public
Founded yearint
2017
Descriptiontext

Landos Biopharma was a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Blacksburg, Virginia, focused on developing orally administered therapeutics for autoimmune diseases, with a primary emphasis on inflammatory bowel disease (IBD) including Crohn's disease and ulcerative colitis. The company's scientific platform centered on the NOD-like receptor (NLR) family of immunometabolic regulators, with its lead clinical asset NX-13 being a first-in-class oral NLRX1 agonist that operates through a dual mechanism combining anti-inflammatory activity with facilitation of epithelial repair. The company had previously advanced a second candidate, BT-11, an oral IBD therapeutic that progressed toward Phase 1 clinical testing before being superseded by NX-13 as the lead program.

The company's core technology targeted NLRX1, a regulatory receptor that modulates immunometabolism and inflammation. NX-13 was being evaluated in the NEXUS Phase 2 proof-of-concept study (NCT05785715), a randomized, multicenter, double-blind, placebo-controlled trial enrolling 80 patients with moderate-to-severe ulcerative colitis testing 250 mg and 750 mg immediate-release doses over a 12-week induction period with a long-term extension phase. The target patient population included approximately 1.6 million Americans and 4 million global IBD sufferers, representing what the company characterized as a $9.2 billion annual market opportunity growing at 25%.

Landos operated as a pre-commercial entity, generating no product revenue during its independent existence. The company was financed through a $10M Series A led by Perceptive Advisors in 2017 and a subsequent $60M financing in 2019 led by Perceptive Advisors and RTW Investments. It maintained a lean organization of 11-50 employees under scientific leadership including Chief Scientific Officer Raquel Hontecillas. On May 23, 2024, AbbVie completed its acquisition of Landos for $212 million ($20.42 per share plus contingent value rights up to $11.14 per share tied to a clinical milestone), bringing NX-13 into AbbVie's immunology pipeline alongside assets such as Rinvoq and Skyrizi. Following the acquisition, Landos ceased operating as an independent entity and its NASDAQ listing under ticker LABP was terminated.

Short descriptiontext

Landos Biopharma was a clinical-stage biopharmaceutical company developing oral NLRX1 agonist therapeutics for inflammatory bowel disease, targeting Crohn's disease and ulcerative colitis patients. It was acquired by AbbVie in May 2024 for $212 million.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBlacksburg, United States
HQ citystring
Blacksburg
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
oral therapeutics, inflammatory bowel disease, NLRX1 agonist, autoimmune disease treatment, small molecule drugs
Industry1 code
PRIMARYHLAKAEAD
Inflammatory Bowel Disease (IBD) Care
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Inflammatory Bowel Disease Therapeutics
Social media profiles1 record
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Landos Biopharma developed orally administered small molecule therapeutics for autoimmune diseases, with a primary focus on inflammatory bowel disease (IBD). Its lead investigational asset, NX-13, is a first-in-class oral NLRX1 agonist with a dual mechanism of action (anti-inflammatory and epithelial repair) currently in Phase 2 clinical development for ulcerative colitis. A second candidate, BT-11, was an oral IBD therapeutic that advanced toward Phase 1 clinical testing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Phase 2 proof-of-concept trial (NEXUS) evaluating 80 patients with moderate to severe UC with 12-week induction study
Product overview1 text field

Landos Biopharma was a biopharmaceutical company focused on developing orally active therapeutics for autoimmune diseases, primarily targeting inflammatory bowel disease (IBD). The company advanced two lead therapeutic candidates: NX-13 (a first-in-class oral NLRX1 agonist currently in Phase 2 for ulcerative colitis) and BT-11 (an oral IBD treatment that previously entered clinical development). The company was acquired by AbbVie in May 2024, bringing NX-13 into AbbVie's immunology pipeline with potential novel approaches to treating UC and Crohn's disease.

Product and service2 records
1NX-13
CategoryOral small molecule therapeutic
Description

First-in-class oral NLRX1 agonist (member of the NOD-like receptor family) for the treatment of ulcerative colitis and Crohn's disease. NLRX1 regulates immunometabolism and inflammation, with a dual mechanism of action that is anti-inflammatory and facilitates epithelial repair. Currently in Phase 2 clinical development as part of AbbVie's pipeline following the 2024 acquisition.

2BT-11
CategoryOral small molecule therapeutic
Description

Oral therapeutic candidate for inflammatory bowel disease (Crohn's disease and ulcerative colitis). Previously Landos' lead therapeutic candidate before NX-13, with planned Phase 1 clinical testing to evaluate safety and efficacy in IBD patients.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-05-23
Description

AbbVie completed acquisition of Landos Biopharma on May 23, 2024. Landos' lead investigational asset NX-13 (first-in-class oral NLRX1 agonist) was added to AbbVie's pipeline with potential to offer novel approach to treatment of ulcerative colitis and Crohn's disease. Acquisition price was $20.42 per share plus up to $11.14 per share contingent value right.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

AbbVie acquired Landos and is itself the dominant IBD player with Skyrizi, Rinvoq, and Humira. It is the most directly comparable benchmark and the acquirer of the NX-13 program, with deep commercial infrastructure in ulcerative colitis and Crohn's disease.

TypeBroad incumbent
Description

Roche has an active IBD pipeline and is a major immunology company that frequently scouts and acquires IBD assets. It represents a potential strategic alternative acquirer and a benchmark for IBD pipeline competition.

TypeDirect peer
Description

Pfizer acquired Arena Pharmaceuticals in 2022 for etrasimod, an oral S1P modulator approved for UC. Pfizer is now one of the leading oral IBD players and a direct competitor in the same prescription setting as NX-13.

TypeDirect peer
Description

Protagonist Therapeutics developed PTG-100 (JNJ-77242113), an oral peptide for UC partnered with J&J. It is a clinical-stage biotech with a directly comparable oral IBD therapeutic profile and partnership trajectory to Landos.

5Bristol-Myers Squibb (Zeposia)
TypeDirect peer
Description

BMS developed Zeposia (ozanimod), an oral S1P modulator approved for moderate-to-severe ulcerative colitis. It competes directly in the oral UC space where Landos's NX-13 would launch, with a similar patient population and prescriber base.

TypeBroad incumbent
Description

Gilead partnered with Galapagos on filgotinib and has broader JAK-inhibitor interests in IBD. It is a comparable large pharma with active UC franchise ambition and parallel oral IBD development programs.

TypeDirect peer
Description

Galapagos developed filgotinib (Jyseleca), a JAK inhibitor for UC, in partnership with Gilead. It is a clinical-stage IBD company comparable in size and strategic positioning to pre-acquisition Landos, with similar exit-or-development dynamics.

TypeBroad incumbent
Description

Takeda markets Entyvio (vedolizumab), a leading biologic for UC and Crohn's disease. As a major IBD franchise holder with established commercial presence, Takeda represents incumbent competition Landos/NX-13 would have displaced or augmented.

TypeDirect peer
Description

Eli Lilly developed mirikizumab (Omvoh), an IL-23 antagonist approved for UC and Crohn's. It is a direct competitor for moderate-to-severe IBD patients and represents the kind of advanced pipeline competitor NX-13 will face at launch.

TypeBroad incumbent
Description

J&J markets Stelara (ustekinumab) and Tremfya in IBD, with a major immunology franchise. J&J also partnered with Protagonist Therapeutics on PTG-100, making it a directly comparable pharma partner and competitor in IBD R&D.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors5 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Landos Biopharma

Inflammatory Bowel Disease Therapeuticslandosbiopharma.com

Landos Biopharma was a clinical-stage biopharmaceutical company developing oral NLRX1 agonist therapeutics for inflammatory bowel disease, targeting Crohn's disease and ulcerative colitis patients. It was acquired by AbbVie in May 2024 for $212 million.

What Landos Biopharma does

Landos Biopharma was a clinical-stage biopharmaceutical company founded in 2017 and headquartered in Blacksburg, Virginia, focused on developing orally administered therapeutics for autoimmune diseases, with a primary emphasis on inflammatory bowel disease (IBD) including Crohn's disease and ulcerative colitis. The company's scientific platform centered on the NOD-like receptor (NLR) family of immunometabolic regulators, with its lead clinical asset NX-13 being a first-in-class oral NLRX1 agonist that operates through a dual mechanism combining anti-inflammatory activity with facilitation of epithelial repair. The company had previously advanced a second candidate, BT-11, an oral IBD therapeutic that progressed toward Phase 1 clinical testing before being superseded by NX-13 as the lead program.

The company's core technology targeted NLRX1, a regulatory receptor that modulates immunometabolism and inflammation. NX-13 was being evaluated in the NEXUS Phase 2 proof-of-concept study (NCT05785715), a randomized, multicenter, double-blind, placebo-controlled trial enrolling 80 patients with moderate-to-severe ulcerative colitis testing 250 mg and 750 mg immediate-release doses over a 12-week induction period with a long-term extension phase. The target patient population included approximately 1.6 million Americans and 4 million global IBD sufferers, representing what the company characterized as a $9.2 billion annual market opportunity growing at 25%.

Landos operated as a pre-commercial entity, generating no product revenue during its independent existence. The company was financed through a $10M Series A led by Perceptive Advisors in 2017 and a subsequent $60M financing in 2019 led by Perceptive Advisors and RTW Investments. It maintained a lean organization of 11-50 employees under scientific leadership including Chief Scientific Officer Raquel Hontecillas. On May 23, 2024, AbbVie completed its acquisition of Landos for $212 million ($20.42 per share plus contingent value rights up to $11.14 per share tied to a clinical milestone), bringing NX-13 into AbbVie's immunology pipeline alongside assets such as Rinvoq and Skyrizi. Following the acquisition, Landos ceased operating as an independent entity and its NASDAQ listing under ticker LABP was terminated.

Landos Biopharma firmographics

Firmographics
Name
Landos Biopharma
Legal name
Landos Biopharma, Inc.
Website
https://landosbiopharma.com
Company type
Public
Founded year
2017
Operating status
Acquired
Headcount range
11–50 employees
Short description
Landos Biopharma was a clinical-stage biopharmaceutical company developing oral NLRX1 agonist therapeutics for inflammatory bowel disease, targeting Crohn's disease and ulcerative colitis patients. It was acquired by AbbVie in May 2024 for $212 million.
Ownership category
akta.pro rank

Landos Biopharma industry classification

Industry
Product category
Inflammatory Bowel Disease Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAKAEAD
Inflammatory Bowel Disease (IBD) Care

Keywords

  • Oral therapeutics
  • Inflammatory bowel disease
  • NLRX1 agonist
  • Autoimmune disease treatment
  • Small molecule drugs

Where Landos Biopharma is headquartered

Location

Headquarters

HQ city
Blacksburg
HQ country
United States
HQ region
North America

Markets served

Landos Biopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Landos Biopharma product offering

Product offering

Core offering

Landos Biopharma developed orally administered small molecule therapeutics for autoimmune diseases, with a primary focus on inflammatory bowel disease (IBD). Its lead investigational asset, NX-13, is a first-in-class oral NLRX1 agonist with a dual mechanism of action (anti-inflammatory and epithelial repair) currently in Phase 2 clinical development for ulcerative colitis. A second candidate, BT-11, was an oral IBD therapeutic that advanced toward Phase 1 clinical testing.

Product overview

Landos Biopharma was a biopharmaceutical company focused on developing orally active therapeutics for autoimmune diseases, primarily targeting inflammatory bowel disease (IBD). The company advanced two lead therapeutic candidates: NX-13 (a first-in-class oral NLRX1 agonist currently in Phase 2 for ulcerative colitis) and BT-11 (an oral IBD treatment that previously entered clinical development). The company was acquired by AbbVie in May 2024, bringing NX-13 into AbbVie's immunology pipeline with potential novel approaches to treating UC and Crohn's disease.

Differentiator

Problem solved

Functional benefit

Products and services

  • NX-13 First-in-class oral NLRX1 agonist (member of the NOD-like receptor family) for the treatment of ulcerative colitis and Crohn's disease. NLRX1 regulates immunometabolism and inflammation, with a dual mechanism of action that is anti-inflammatory and facilitates epithelial repair. Currently in Phase 2 clinical development as part of AbbVie's pipeline following the 2024 acquisition.
  • BT-11 Oral therapeutic candidate for inflammatory bowel disease (Crohn's disease and ulcerative colitis). Previously Landos' lead therapeutic candidate before NX-13, with planned Phase 1 clinical testing to evaluate safety and efficacy in IBD patients.

Quantifiable outcome

  • Phase 2 proof-of-concept trial (NEXUS) evaluating 80 patients with moderate to severe UC with 12-week induction study

Companies that use Landos Biopharma

Customer profile

Segments2 records

Ideal customer profiles2 records

Landos Biopharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Landos Biopharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • AbbViecoreStrategic or Co-development Partner · 23 May 2024AbbVie completed acquisition of Landos Biopharma on May 23, 2024. Landos' lead investigational asset NX-13 (first-in-class oral NLRX1 agonist) was added to AbbVie's pipeline with potential to offer novel approach to treatment of ulcerative colitis and Crohn's disease. Acquisition price was $20.42 per share plus up to $11.14 per share contingent value right.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Landos Biopharma competitors and assessment

Company assessment

Broad incumbents

  • AbbVie: AbbVie acquired Landos and is itself the dominant IBD player with Skyrizi, Rinvoq, and Humira. It is the most directly comparable benchmark and the acquirer of the NX-13 program, with deep commercial infrastructure in ulcerative colitis and Crohn's disease.
  • Roche: Roche has an active IBD pipeline and is a major immunology company that frequently scouts and acquires IBD assets. It represents a potential strategic alternative acquirer and a benchmark for IBD pipeline competition.
  • Gilead Sciences: Gilead partnered with Galapagos on filgotinib and has broader JAK-inhibitor interests in IBD. It is a comparable large pharma with active UC franchise ambition and parallel oral IBD development programs.
  • Takeda (Entyvio): Takeda markets Entyvio (vedolizumab), a leading biologic for UC and Crohn's disease. As a major IBD franchise holder with established commercial presence, Takeda represents incumbent competition Landos/NX-13 would have displaced or augmented.
  • Johnson & Johnson (Stelara/Tremfya): J&J markets Stelara (ustekinumab) and Tremfya in IBD, with a major immunology franchise. J&J also partnered with Protagonist Therapeutics on PTG-100, making it a directly comparable pharma partner and competitor in IBD R&D.

Direct peers

  • Pfizer: Pfizer acquired Arena Pharmaceuticals in 2022 for etrasimod, an oral S1P modulator approved for UC. Pfizer is now one of the leading oral IBD players and a direct competitor in the same prescription setting as NX-13.
  • Protagonist Therapeutics: Protagonist Therapeutics developed PTG-100 (JNJ-77242113), an oral peptide for UC partnered with J&J. It is a clinical-stage biotech with a directly comparable oral IBD therapeutic profile and partnership trajectory to Landos.
  • Bristol-Myers Squibb (Zeposia): BMS developed Zeposia (ozanimod), an oral S1P modulator approved for moderate-to-severe ulcerative colitis. It competes directly in the oral UC space where Landos's NX-13 would launch, with a similar patient population and prescriber base.
  • Galapagos NV: Galapagos developed filgotinib (Jyseleca), a JAK inhibitor for UC, in partnership with Gilead. It is a clinical-stage IBD company comparable in size and strategic positioning to pre-acquisition Landos, with similar exit-or-development dynamics.
  • Eli Lilly (Omvoh): Eli Lilly developed mirikizumab (Omvoh), an IL-23 antagonist approved for UC and Crohn's. It is a direct competitor for moderate-to-severe IBD patients and represents the kind of advanced pipeline competitor NX-13 will face at launch.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Landos Biopharma social profiles

Digital presence

Landos Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Landos Biopharma leadership team

Management profile

Number of profiles

Profiles1 record

Landos Biopharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Landos Biopharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Landos Biopharma

What does Landos Biopharma do?

Landos Biopharma developed orally administered small molecule therapeutics for autoimmune diseases, with a primary focus on inflammatory bowel disease (IBD). Its lead investigational asset, NX-13, is a first-in-class oral NLRX1 agonist with a dual mechanism of action (anti-inflammatory and epithelial repair) currently in Phase 2 clinical development for ulcerative colitis. A second candidate, BT-11, was an oral IBD therapeutic that advanced toward Phase 1 clinical testing.

Is Landos Biopharma a public or private company?

Landos Biopharma is a public company. It is classified as corporate owned and is currently acquired.

When was Landos Biopharma founded?

Landos Biopharma was founded in 2017. It employs 11 to 50 people.

Where is Landos Biopharma based?

Landos Biopharma is headquartered in Blacksburg, United States, in the North America region.

Who are Landos Biopharma's main competitors?

Broad incumbents on record are AbbVie, Roche, Gilead Sciences, Takeda (Entyvio) and Johnson & Johnson (Stelara/Tremfya). Direct peers are Pfizer, Protagonist Therapeutics, Bristol-Myers Squibb (Zeposia), Galapagos NV and Eli Lilly (Omvoh).

Does Landos Biopharma have an API?

No public API is recorded for Landos Biopharma.

What industry is Landos Biopharma in?

Landos Biopharma's product category is Inflammatory Bowel Disease Therapeutics. Its primary akta.pro industry code is HLAKAEAD, Inflammatory Bowel Disease (IBD) Care. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
NimmlLandos Biopharma Raises $10 Million to Develop New Therapeutics for Autoimmune DiseasesLandos Biopharma has secured $10 million in Series A funding through Perceptive Advisors to advance its pharmaceutical pipeline for autoimmune diseases toward clinical trials and commercialization. The funding will support Phase 1 clinical testing of the company's lead therapeutic candidate BT-11, an oral treatment for inflammatory bowel disease (Crohn's disease and ulcerative colitis), in the second half of 2018. The IBD market represents a $9.2 billion annual opportunity growing at 25%, with approximately 1.6 million American and 4 million global sufferers currently seeking safer, more effective treatments.AbbvieAbbVie Completes Acquisition of Landos BiopharmaAbbVie has completed its acquisition of Landos Biopharma, integrating the company into its operations and adding Landos' investigational asset NX-13 to its pipeline. The transaction valued Landos at $20.42 per share plus contingent value rights up to $11.14 per share, pending specific clinical development milestones. This move aims to expand AbbVie's capabilities in treating ulcerative colitis and Crohn's disease through a novel oral NLRX1 agonist.PR NewswireStockholder Alert: Ademi LLP continues Investigation of the Fairness of Landos Biopharma, Inc.'s transaction with AbbVieLaw firm Ademi LLP announced an investigation into the fairness of Landos Biopharma's proposed acquisition by AbbVie, prompting shareholders to consider joining the case. In the transaction, Landos shareholders would receive $20.42 per share in cash (approximately $137.5 million total) plus one non-tradable contingent value right worth up to $11.14 per share (approximately $75 million additional) contingent on clinical development milestones. The law firm claims the deal agreement unreasonably restricts competing transactions through significant penalties and that Landos insiders would receive substantial change-of-control benefits.PR NewswireSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Landos Biopharma, Inc - LABPMonteverde & Associates PC announced an investigation into Landos Biopharma, Inc. regarding its proposed acquisition by AbbVie, Inc. Under the agreement terms, Landos shareholders are set to receive $20.42 in cash plus a contingent value right potentially worth up to $11.14 per share.BenzingaWhy Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday’s MidAbbVie Inc. entered into a definitive agreement to acquire Landos Biopharma, causing Landos shares to surge 171.2% to $21.70 on Monday. The article also highlights significant stock movements across other biotech and tech firms, including Lucid Group's announcement of a $1 billion investment from a PIF affiliate and Esperion Therapeutics receiving FDA approval for broad labels on its cardiovascular drugs.Pulse 2.0AbbVie Buying Landos Biopharma In $137.5 Million DealAbbVie agreed to acquire Landos Biopharma for $20.42 per share, about $137.5 million, plus a contingent value right worth up to $75 million. The deal targets NX-13, an oral NLRX1 agonist for ulcerative colitis and Crohn's disease, with a Phase 2 trial now enrolling patients in the US and Europe.GlobeNewswireAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesAbbVie agreed to acquire Landos Biopharma, a clinical-stage biopharmaceutical company, at $20.42 per share in cash, plus contingent value rights. The deal, expected to close in Q2 2024, aims to advance NX-13, an oral NLRX1 agonist for ulcerative colitis and Crohn's disease, with a Phase 2 trial enrolling patients.BenzingaWhy Is Ulcerative Colitis-Focused Landos Biopharma Stock Trading Higher On Monday?AbbVie Inc agreed to acquire Landos Biopharma Inc for $20.42 per share, representing approximately $137.5 million in aggregate equity value, plus one contingent value right of up to $11.14 per share (approximately $75 million additional) in a deal expected to close in Q2 2024. Landos' lead asset NX-13 is a first-in-class, oral NLRX1 agonist currently enrolling patients in a Phase 2 clinical trial for ulcerative colitis in the United States and Europe. The acquisition aims to advance the clinical development of NX-13, which has potential applications in both ulcerative colitis and Crohn's disease.AbbvieAbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune DiseasesAbbVie Inc. has entered into a definitive agreement to acquire Landos Biopharma for approximately $137.5 million in cash, plus potential contingent value rights worth up to an additional $75 million. The transaction is driven by AbbVie's interest in Landos' lead asset NX-13, a first-in-class oral NLRX1 agonist currently in Phase 2 trials for ulcerative colitis. The deal is expected to close in the second quarter of 2024, subject to stockholder approval and customary closing conditions.PR NewswireShareholder Alert: Ademi LLP investigates whether Landos Biopharma, Inc. has obtained a Fair Price in its transaction with AbbVieLaw firm Ademi LLP announced an investigation into Landos Biopharma's board of directors regarding their handling of the acquisition by AbbVie, specifically examining whether shareholders are receiving fair value. Under the transaction terms, Landos shareholders would receive $20.42 per share in cash plus non-tradable contingent value rights worth up to $11.14 per share additional, totaling approximately $212.5 million if all milestones are met. The law firm alleges the deal unreasonably penalizes competing bids and that insiders will receive change-of-control benefits not available to ordinary shareholders.